Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2021 | Treatment de-intensification strategies for head and neck cancer

Ari Rosenberg, MD, University of Chicago Medical Center, Chicago, IL, discusses promising new strategies for treatment de-intensification for head and neck cancer. These strategies are typically focused on patients with human papillomavirus (HPV) -associated head and neck cancer who have a favorable prognosis. Possible de-intensification strategies include replacing cytotoxic chemotherapy with targeted therapies including rituximab, de-intensifying adjuvant treatment after minimally-invasive surgery, and response-adapted de-intensification. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.